Across TCGA pan-cancer cohorts, SLC26A1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLC26A1 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in kidney chromophobe (KICH), where higher SLC26A1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC26A1 expression acts as an unfavorable survival marker.
KICH, BLCA, and UCEC are the cancer types where SLC26A1 Mutation most reproducibly stratifies survival.